stockrowBiogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- −104.4%
- Free cash flow
- −69.3%
- Total debt
- +16.0%
Quarter to September 2026, against a year earlier
Follow BIIB
Alert me
Biogen Inc. (BIIB) Current ratio
Biogen Inc.'s current ratio at the end of the quarter to 30 September 2026 was 1.9×, down 0.7× from fiscal 2025 (2.7×). Over the past ten years it has ranged from 1.3× (fiscal 2024) to 3.0× (fiscal 2022); the current reading is higher than 91% of that period. That is above the Drug Manufacturers General industry median of 1.4× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.7× | 98.66% |
| FY2024 | 1.3× | (32.47%) |
| FY2023 | 2.0× | (33.24%) |
| FY2022 | 3.0× | 63.67% |
| FY2021 | 1.8× | (0.68%) |
| FY2020 | 1.8× | 6.80% |
| FY2019 | 1.7× | (25.68%) |
| FY2018 | 2.3× | (0.80%) |
| FY2017 | 2.3× | (8.45%) |
| FY2016 | 2.6× | (1.77%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 1.9× | 4.31% |
| Jun 2026 | 1.9× | (39.14%) |
| Mar 2026 | 3.1× | 14.38% |
| Dec 2025 | 2.7× | (1.36%) |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| BIIB Biogen Inc. | 1.9× |
| BMY Bristol Myers Squibb Company compare | 1.6× |
| AMGN Amgen Inc. compare | 1.5× |
| PFE Pfizer Inc. compare | 1.4× |
| GILD Gilead Sciences, Inc. compare | 1.4× |
| SNY Sanofi compare | 1.1× |
| AZN AstraZeneca PLC compare | 1.0× |
| NVO Novo Nordisk A/S compare | 0.9× |
| GSK GSK PLC Sponsored ADR compare | 0.9× |
| Drug Manufacturers General industry median | 1.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement